NVK-002

· Vyluma, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NVK-002, covering 2024-11-27 to 2024-11-27. Get the full timeline:

Most recent: Clinical Trial Update: CHAMP: Study of NVK-002 in Children With Myopia [Phase 3]